What is the recovery time after stem cell therapy for Scleroderma (Systemic Sclerosis)?
Recovery and risk differ radically between an outpatient investigational infusion and autologous HSCT with mobilisation and conditioning chemotherapy. No single timeline is valid. The treating team must provide intervention-specific information on hospitalisation, infection and organ monitoring, emergency arrangements, activity restrictions and long-term follow-up.
What the evidence shows for Scleroderma (Systemic Sclerosis)
Randomised evidence and specialist recommendations support considering autologous HSCT for carefully selected severe early diffuse disease, while recognising substantial treatment-related risk. That evidence cannot be transferred to placental MSC infusion: the products, conditioning, mechanism, risks and endpoints are fundamentally different. MSC studies remain early and heterogeneous. No combined response rate is published here. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Scleroderma (Systemic Sclerosis): full overview → · Scleroderma (Systemic Sclerosis) cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Scleroderma (Systemic Sclerosis): cell-therapy evidence and registered trials
- How much does stem cell therapy for Scleroderma (Systemic Sclerosis) cost? (2026)
- Scleroderma (Systemic Sclerosis) stem cell therapy — your questions answered (2026)
- Scleroderma (Systemic Sclerosis): cell-therapy evidence by therapy class
- MSC vs HSCT for Scleroderma (Systemic Sclerosis): what the registries show